机构:[1]Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing/China,[2]Radiation Oncology, The First Affiliated Hospital of Kunming Medical College, Kunming/China,肿瘤放疗科昆明医科大学附属第一医院[3]Cancer Center of People’S Liberation Army, Xinqiao Hospital, Third Military Medical University, Chongqing/China
第一作者机构:[1]Daping Hospital and the Research Institute of Surgery of the Third Military Medical University, Chongqing/China,
推荐引用方式(GB/T 7714):
Yang Zhen-Zhou,Li Rong-Qing,Zhu Bo.Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC[J].JOURNAL OF THORACIC ONCOLOGY.2015,10(9):S426-S427.
APA:
Yang, Zhen-Zhou,Li, Rong-Qing&Zhu, Bo.(2015).Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC.JOURNAL OF THORACIC ONCOLOGY,10,(9)
MLA:
Yang, Zhen-Zhou,et al."Phase III Study of WBRT with or without Erlotinib for Brain Metastasis NSCLC".JOURNAL OF THORACIC ONCOLOGY 10..9(2015):S426-S427